NAD+
Case StudyAcross thousands of community-reported NAD+ cycles, the modal experience converges on incremental rather than dramatic effects. Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle Critically, NAD+ is the substrate consumed by sirtuins (SIRT1-7) and PARPs — both depend on adequate NAD+ for their longevity- and DNA-repair-related functions. NAD+ levels decline approximately 50% from age 20 to 60.. Users report effects emerging across 4-8 weeks at the 100-1000 mg 1x weekly iv; daily subq at lower doses dose; first-cycle reports tend to undersell the response, second-cycle reports tend to oversell, and the honest middle is what experienced users describe.
Key Takeaways
Community lens: aggregated reports on NAD+ converge on incremental rather than dramatic effects over 4-8 weeks. Mechanism: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Reported non-response rate: 15-25% of users describe absent or partial response at 100-1000 mg 1x weekly iv; daily subq at lower doses dosing. Community dose-range convergence: research-dose range produces modal response; substantial upward adjustment produces diminishing returns. Community-favoured stack partners: BPC-157, TB-500, Ipamorelin.
Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Critically, NAD+ is the substrate consumed by sirtuins (SIRT1-7) and PARPs — both depend on adequate NAD+ for their longevity- and DNA-repair-related functions. NAD+ levels decline approximately 50% from age 20 to 60. The community translation of this mechanism: what users report at the modal dose, the diary patterns that emerge across many reports, the stack combinations the community converges on, and the honest non-response rate that experienced users discuss but novice users often miss.
Stacking patterns and community wisdom
The most-reported NAD+ stack combinations rotate through Nicotinamide adenine dinucleotide, β-NAD and the canonical pairings appropriate to its mechanism. Community convergence on these patterns is one of the most useful signals for new users — not because the community is always right, but because the well-tolerated combinations have been filtered over many cycles.
What works and what doesn't
Honesty about non-response is one of the more useful contributions of community reporting. Roughly 15–25% of users report that NAD+ did not produce the expected effect for their specific use case. The most-cited reasons: dose timing relative to food, vendor quality issues, expectations calibrated to dramatic stories rather than the actual modest profile, and stacking complexity that masked the individual contribution.
Common dosing diary patterns
User dosing diaries converge on 100-1000 mg as the standard, with experienced users sometimes adjusting upward by 25–50% and reporting diminishing returns thereafter. The diary patterns also show that subcutaneous administration is the dominant route, and that consistency matters more than absolute dose.
For subjective effect timeline, community first-cycle reports on NAD+ tend to undersell the response, while second-cycle reports tend to oversell. The honest middle is what experienced users describe — modest, consistent, and worth the protocol effort for users with baseline-appropriate indications.
Community dosing diaries for NAD+ in side effect reports converge on consistent dosing patterns. The shared wisdom is more useful than any individual report — not because the community is always right but because consistent patterns across many users filter idiosyncratic experiences.
Quality Reports is one of the more-reported community use cases for NAD+. The aggregate experience pattern: most users report incremental benefit within 4–8 weeks, a minority report no response, and dramatic responses are rare. Setting expectations to the modal experience improves user satisfaction.
For onset & duration, community first-cycle reports on NAD+ tend to undersell the response, while second-cycle reports tend to oversell. The honest middle is what experienced users describe — modest, consistent, and worth the protocol effort for users with baseline-appropriate indications.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | IV | 100-1000 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | IV | 60-1000 mg | 4–6 weeks initial cycle |
| Case Study focus | IV | 100-1000 mg | 1x weekly IV; daily SubQ at lower doses |
| Maintenance phase | IV | 70-1000 mg | Ongoing with periodic pauses |
Dose timing for NAD+ is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
NAD+ stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the experienced peptide community.
- NAD+ + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with NAD+'s mechanism in first-person / case studies protocols.
- NAD+ + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with NAD+'s mechanism in first-person / case studies protocols.
- NAD+ + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with NAD+'s mechanism in first-person / case studies protocols.
- NAD+ + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with NAD+'s mechanism in first-person / case studies protocols.
Flushing common with IV (rate-dependent). Mild GI upset. Pretreatment with niacinamide can reduce flush.
Lens-specific safety considerations for first-person / case studies use of NAD+: Flushing common with IV (rate-dependent). Mild GI upset. Pretreatment with niacinamide can reduce flush. Additional first-person / case studies monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| NAD+ | Pyridine nucleotide cofactor | Hours; cellular pool dynamic | Case Study |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
What does NAD+ actually feel like?
What about peptide-quality variation between vendors?
Is NAD+ a good first peptide?
Best practice for storage and travel?
What is the regulatory status of NAD+?
What is the standard dosing protocol for NAD+?
Start a NAD+ Protocol
Alukard provides physician-supervised protocols with GMP-certified NAD+ and GMP-certified compounds dispensed with personalised dosing protocols.
Get ProtocolQuick Facts
- Molecular weight
- 663 Da
- Half-life
- Hours; cellular pool dynamic
- WADA
- Not on prohibited list
- FDA
- Approved by various routes for various uses; mass-dose IV is off-label
Stack Partners
All first-person / case studies applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for NAD+ unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your First-Person / Case Studies Protocol for NAD+
Alukard provides physician-supervised protocols with GMP-certified compounds dispensed with personalised dosing protocols.
HIPAA Compliant · GMP Certified · Physician Supervised